{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:35:09Z","timestamp":1791462909817,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>In a healthy gut microbiota, short chain fatty acids (SCFAs) are produced. The antibacterial action of SCFAs against intestinal pathogens makes them useful for ensuring the safety of food and human health. In this study, we aimed to assess the in vitro inhibitory activity of SCFAs, and to report, for the first time, their impact on the activity of new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. The minimum inhibitory concentrations of acetic, propionic, and butyric acids were determined against <jats:italic>E. coli<\/jats:italic> clinical isolates recovered from gastrointestinal infections. Cefoperazone\/sulbactam, ceftazidime\/avibactam and cefepime\/enmetazobactam are new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations that were studied for their combined therapeutic effects. Also, the effects of pH and concentration of SCFAs were evaluated on in vitro bacterial growth and expression of genes encoding for motility, adhesion, invasion, and biofilm formation. SCFAs were tested at concentrations of 12\u2009mM at pH 7.4 (ileum-conditions), in addition to 60\u2009mM and 123\u2009mM, at pH 6.5 (colon-conditions). The tested SCFAs showed the same MIC (3750\u2009\u03bcg\u2009ml<jats:sup>\u22121<\/jats:sup> \u2243 60\u2009mM) against all isolates. Furthermore, the addition of SCFAs to the tested \u03b2-lactam\/\u03b2-lactamase inhibitor combinations greatly restored the susceptibility of the isolates. SCFAs had significant effect on bacterial growth and virulence in a pH and concentration-dependent manner; low ileal concentration potentiated <jats:italic>E. coli<\/jats:italic> growth, while higher colonic concentration significantly suppressed growth and down-regulated the expression of virulence genes (<jats:italic>fliC, ipaH, FimH, BssS<\/jats:italic>). Therefore, the significant inhibitory effect of colonic SCFAs on \u03b2-lactam\/\u03b2-lactamase inhibitor combinations might lead to the development of promising treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41429-023-00595-1","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T09:05:42Z","timestamp":1675242342000},"page":"225-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and on virulence of Escherichia coli isolates"],"prefix":"10.1038","volume":"76","author":[{"given":"Ashraf A.","family":"Kadry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May A.","family":"El-Antrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira M.","family":"El-Ganiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1128\/JB.01480-09","volume":"192","author":"KP Williams","year":"2010","unstructured":"Williams KP, Gillespie JJ, Sobral BWS, Nordberg EK, Snyder EE, Shallom JM, et al. Phylogeny of gammaproteobacteria. J Bacteriol [Internet] 2010;192:2305\u201314. Available from: https:\/\/doi.org\/10.1128\/JB.01480-09. [cited 2022 Jun 8]","journal-title":"J Bacteriol [Internet]"},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrmicro818","volume":"2","author":"JB Kaper","year":"2004","unstructured":"Kaper JB, Nataro JP, Mobley HLT. Pathogenic escherichia coli. Nat Rev Microbiol. 2004;2:123\u201340.","journal-title":"Nat Rev Microbiol"},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"9922","DOI":"10.3390\/ijms22189922","volume":"22","author":"B Pakbin","year":"2021","unstructured":"Pakbin B, Br\u00fcck WM, Rossen JWA. Virulence factors of enteric pathogenic Escherichia coli: A review. Int J Mol Sci. 2021;22:9922.","journal-title":"Int J Mol Sci"},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-019-1587-3","volume":"19","author":"C Shah","year":"2019","unstructured":"Shah C, Baral R, Bartaula B, Shrestha LB. Virulence factors of uropathogenic Escherichia coli (UPEC) and correlation with antimicrobial resistance. BMC Microbiol. 2019;19:1\u20136.","journal-title":"BMC Microbiol"},{"key":"595_CR5","first-page":"238","volume":"20","author":"A Kadry","year":"2020","unstructured":"Kadry A, Al-Kashef N, sciences AEGA health, 2020 undefined. Distribution of genes encoding adhesins and biofilm formation capacity among Uropathogenic Escherichia coli isolates in relation to the antimicrobial resistance. ajol info [Internet] 2020;20:238. Available from: https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/195012 [cited 2022 Jun 8]","journal-title":"ajol info [Internet]"},{"key":"595_CR6","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.3390\/molecules26196057","volume":"26","author":"SB Christensen","year":"2021","unstructured":"Christensen SB. Drugs that changed society: History and current status of the early antibiotics: Salvarsan, sulfonamides, and \u03b2-lactams. Molecules 2021;26:6057.","journal-title":"Molecules"},{"key":"595_CR7","doi-asserted-by":"crossref","unstructured":"Pitout JDD Extraintestinal pathogenic Escherichia coli: A combination of virulence with antibiotic resistance. Front Microbiol. 2012;3(JAN).","DOI":"10.3389\/fmicb.2012.00009"},{"key":"595_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/09674845.2017.1278884","volume":"74","author":"AA Kadry","year":"2017","unstructured":"Kadry AA, Serry FM, El-Ganiny AM, El-Baz AM. Integron occurrence is linked to reduced biocide susceptibility in multidrug resistant Pseudomonas aeruginosa. Br J Biomed Sci. 2017;74:78\u201384.","journal-title":"Br J Biomed Sci"},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum \u03b2-lactamases: A clinical update. Clin Microbiol Rev. 2005;18:657\u201386.","journal-title":"Clin Microbiol Rev"},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"106377","DOI":"10.1016\/j.ijantimicag.2021.106377","volume":"58","author":"YL Lee","year":"2021","unstructured":"Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, et al. In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020. Int J Antimicrob Agents. 2021;58:106377.","journal-title":"Int J Antimicrob Agents"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","volume":"20","author":"KM Papp-Wallace","year":"2019","unstructured":"Papp-Wallace KM. The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother. 2019;20:2169\u201384.","journal-title":"Expert Opin Pharmacother"},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/ph15040476","volume":"15","author":"S Alfei","year":"2022","unstructured":"Alfei S, Schito AM. \u03b2-Lactam Antibiotics and \u03b2-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals 2022;15:476.","journal-title":"Pharmaceuticals"},{"key":"595_CR13","doi-asserted-by":"publisher","first-page":"IV23","DOI":"10.1093\/jac\/dkab352","volume":"76","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021;76:IV23\u201337.","journal-title":"J Antimicrob Chemother"},{"key":"595_CR14","first-page":"466","volume":"14","author":"AA Kadry","year":"2022","unstructured":"Kadry AA, El-Antrawy MA, El-Ganiny AM. Management of clinical infections of Escherichia coli by new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Iran J Microbiol. 2022;14:466\u201374.","journal-title":"Iran J Microbiol"},{"key":"595_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/genes9020102","volume":"9","author":"F Bishehsari","year":"2018","unstructured":"Bishehsari F, Engen PA, Preite NZ, Tuncil YE, Naqib A, Shaikh M, et al. Dietary fiber treatment corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon carcinogenesis. Genes 2018;9:102.","journal-title":"Genes"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics9080462","volume":"9","author":"S Zhang","year":"2020","unstructured":"Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, et al. Short chain fatty acids modulate the growth and virulence of pathosymbiont escherichia coli and host response. Antibiotics 2020;9:1\u201320.","journal-title":"Antibiotics"},{"key":"595_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189\u2013200.","journal-title":"Gut Microbes"},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"103293","DOI":"10.1016\/j.ebiom.2021.103293","volume":"66","author":"S Deleu","year":"2021","unstructured":"Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine 2021;66:103293.","journal-title":"EBioMedicine"},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/antibiotics8040265","volume":"8","author":"A Lamas","year":"2019","unstructured":"Lamas A, Regal P, V\u00e1zquez B, Cepeda A, Franco CM. Short chain fatty acids commonly produced by gut microbiota influence Salmonella enterica motility, biofilm formation, and gene expression. Antibiotics 2019;8:265.","journal-title":"Antibiotics"},{"key":"595_CR20","unstructured":"Washington C, Stephen A, Janda W Koneman\u2019s color atlas and textbook of diagnostic microbiology. USA: Lippincott williams & wilkins; 2006."},{"key":"595_CR21","unstructured":"Clinical and Laboratory Standards Institute (2017). Performance standards for antimicrobial disk susceptibility tests; approved standard\u2014 Twelfth Edition. CLSI document M02-A11. CLSI, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania, USA."},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","volume":"267","author":"J O\u2019Brien","year":"2000","unstructured":"O\u2019Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 2000;267:5421\u20136.","journal-title":"Eur J Biochem"},{"key":"595_CR23","unstructured":"Brown A, Smith H Benson\u2019s Microbiological Applications, Laboratory Manual in General Microbiology, Short Version. McGraw-Hill Education; 2014."},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mimet.2018.02.011","volume":"147","author":"E Villa-Rodr\u00edguez","year":"2018","unstructured":"Villa-Rodr\u00edguez E, Ibarra-G\u00e1mez C, de Los Santos-Villalobos S. Extraction of high-quality RNA from Bacillus subtilis with a lysozyme pre-treatment followed by the Trizol method. J Microbiol Methods. 2018;147:14\u20136.","journal-title":"J Microbiol Methods"},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5414\/CNP71501","volume":"71","author":"J Salo","year":"2009","unstructured":"Salo J, Sevander JJ, Tapiainen T, Ik\u00e4heimo I, Pokka T, Koskela M, et al. Biofilm formation by Escherichia coli isolated from patients with urinary tract infections. Clin Nephrol. 2009;71:501\u20137.","journal-title":"Clin Nephrol"},{"key":"595_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05664-6","volume":"20","author":"RMM Khairy","year":"2020","unstructured":"Khairy RMM, Fathy ZA, Mahrous DM, Mohamed ES, Abdelrahim SS. Prevalence, phylogeny, and antimicrobial resistance of Escherichia coli pathotypes isolated from children less than 5 years old with community acquired-diarrhea in Upper Egypt. BMC Infect Dis. 2020;20:1\u20139.","journal-title":"BMC Infect Dis"},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0021-9797(85)90004-9","volume":"104","author":"M Fletcher","year":"1985","unstructured":"Fletcher M, Pringle JH. The effect of surface free energy and medium surface tension on bacterial attachment to solid surfaces. J Colloid Interface Sci. 1985;104:5\u201314.","journal-title":"J Colloid Interface Sci"},{"key":"595_CR28","doi-asserted-by":"crossref","unstructured":"Michael CA, Dominey-Howes D, Labbate M The antimicrobial resistance crisis: Causes, consequences, and management. Front Public Health. 2014 Sep;2(SEP).","DOI":"10.3389\/fpubh.2014.00145"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"e0251594","DOI":"10.1371\/journal.pone.0251594","volume":"16","author":"SM Khalifa","year":"2021","unstructured":"Khalifa SM, Abd El-Aziz AM, Hassan R, Abdelmegeed ES. \u03b2-lactam resistance associated with \u03b2-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae. PLoS One 2021;16:e0251594.5","journal-title":"PLoS One"},{"key":"595_CR30","first-page":"86","volume":"49","author":"KA Toussaint","year":"2014","unstructured":"Toussaint KA, Gallagher JC. Combinations: From Then to Now. Ann Pharm. 2014;49:86\u201398.","journal-title":"Ann Pharm"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.meegid.2021.104707","volume":"88","author":"YH Ku","year":"2021","unstructured":"Ku YH, Yu WL. Cefoperazone\/sulbactam: New composites against multiresistant gram negative bacteria? Infect Genet Evol. 2021;88:104707.","journal-title":"Infect Genet Evol"},{"key":"595_CR32","doi-asserted-by":"crossref","unstructured":"Yang X, Wang D, Zhou Q, Nie F, Du H, Pang X, et al. Antimicrobial susceptibility testing of Enterobacteriaceae: Determination of disk content and Kirby-Bauer breakpoint for ceftazidime\/avibactam. BMC Microbiol. 2019 Nov;19.","DOI":"10.1186\/s12866-019-1613-5"},{"key":"595_CR33","doi-asserted-by":"publisher","unstructured":"Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from US and European Hospitals during 2014\u20132015. Am Soc Microbiol [Internet]. 2019 [cited 2022 Jun 8];63. Available from: https:\/\/doi.org\/10.1128\/AAC.00514-19","DOI":"10.1128\/AAC.00514-19"},{"key":"595_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/ijms23031105","volume":"23","author":"P Portincasa","year":"2022","unstructured":"Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E, et al. Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. Int J Mol Sci. 2022;23:1105.","journal-title":"Int J Mol Sci"},{"key":"595_CR35","doi-asserted-by":"publisher","first-page":"112352","DOI":"10.1016\/j.biopha.2021.112352","volume":"145","author":"R Mirzaei","year":"2022","unstructured":"Mirzaei R, Dehkhodaie E, Bouzari B, Rahimi M, Gholestani A, Hosseini-Fard SR, et al. Dual role of microbiota-derived short-chain fatty acids on host and pathogen. Biomed Pharmacother. 2022;145:112352.","journal-title":"Biomed Pharmacother"},{"key":"595_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/gut.28.10.1221","volume":"28","author":"JH Cummings","year":"1987","unstructured":"Cummings JH, Pomare EW, Branch WJ, Naylor CP, MacFarlane G. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987;28:1221\u20137.","journal-title":"Gut"},{"key":"595_CR37","first-page":"57","volume":"72","author":"GT Macfarlane","year":"1992","unstructured":"Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol. 1992;72:57\u201364.","journal-title":"J Appl Bacteriol"},{"key":"595_CR38","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1080\/10408398.2016.1203286","volume":"57","author":"M Peng","year":"2017","unstructured":"Peng M, Biswas D. Short chain and polyunsaturated fatty acids in host gut health and foodborne bacterial pathogen inhibition. Crit Rev Food Sci Nutr. 2017;57:3987\u20134002.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"595_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2527\/asasann.2017.031","volume":"95","author":"C Sol","year":"2017","unstructured":"Sol C, Oddo JM, Puyalto M, Carvajal A, G\u00f3mez M, Costillas S, et al. In vitro evaluation of the antimicrobial activity of several short-and medium-chain fatty acid salts and their combinations. J Anim Sci. 2017;95:15.","journal-title":"J Anim Sci"},{"key":"595_CR40","doi-asserted-by":"publisher","first-page":"e0136190","DOI":"10.1371\/journal.pone.0136190","volume":"10","author":"FD Halstead","year":"2015","unstructured":"Halstead FD, Rauf M, Moiemen NS, Bamford A, Wearn CM, Fraise AP, et al. The antibacterial activity of acetic acid against biofilm-producing pathogens of relevance to burns patients. PloS One. 2015;10:e0136190.","journal-title":"PloS One"},{"key":"595_CR41","doi-asserted-by":"crossref","unstructured":"He Y, Xu T, Fossheim LE, Zhang XH FliC, a flagellin protein, is essential for the growth and virulence of fish pathogen Edwardsiella tarda. 2012;","DOI":"10.1371\/journal.pone.0045070"},{"key":"595_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.chom.2018.12.010","volume":"25","author":"W Elhenawy","year":"2019","unstructured":"Elhenawy W, Tsai CN, Coombes BK. Host-specific adaptive diversification of Crohn\u2019s disease-associated adherent-invasive Escherichia coli. Cell Host Microbe. 2019;25:301\u201312.","journal-title":"Cell Host Microbe"},{"key":"595_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/antibiotics9080462","volume":"9","author":"S Zhang","year":"2020","unstructured":"Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, et al. Short chain fatty acids modulate the growth and virulence of pathosymbiont Escherichia coli and host response. Antibiotics 2020;9:462.","journal-title":"Antibiotics"},{"key":"595_CR44","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1099\/mic.0.000357","volume":"162","author":"T Lackraj","year":"2016","unstructured":"Lackraj T, Kim JI, Tran SLY, Foster DEB. Differential modulation of flagella expression in enterohaemorrhagic Escherichia coli O157: H7 by intestinal short-chain fatty acid mixes. Microbiology 2016;162:1761\u201372.","journal-title":"Microbiology"},{"key":"595_CR45","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1039\/C7RA13480K","volume":"8","author":"FJ Osonga","year":"2018","unstructured":"Osonga FJ, Akgul A, Yazgan I, Akgul A, Ontman R, Kariuki VM, et al. Flavonoid-derived anisotropic silver nanoparticles inhibit growth and change the expression of virulence genes in Escherichia coli SM10. RSC Adv. 2018;8:4649\u201361.","journal-title":"RSC Adv"},{"key":"595_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/antibiotics10020161","volume":"10","author":"HR Kim","year":"2021","unstructured":"Kim HR, Eom YB. Synergistic activity of equol and meropenem against carbapenem-resistant Escherichia coli. Antibiotics 2021;10:161.","journal-title":"Antibiotics"},{"key":"595_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1469-0691.2007.01692.x","volume":"13","author":"S Persson","year":"2007","unstructured":"Persson S, Olsen KEP, Scheutz F, Krogfelt KA, Gerner-Smidt P. A method for fast and simple detection of major diarrhoeagenic Escherichia coli in the routine diagnostic laboratory. Clin Microbiol Infect. 2007;13:516\u201324.","journal-title":"Clin Microbiol Infect"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-023-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-023-00595-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-023-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:04:59Z","timestamp":1679871899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-023-00595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1038\/s41429-023-00595-1","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"4 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental tests were carried according to the approval number (FPDU13\/2022) from Faculty of Pharmacy, Delta University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}